These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

76 related items for PubMed ID: 1675782

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation.
    Lehtola L, Sistonen L, Koskinen P, Lehväslaiho H, Di Renzo MF, Comoglio PM, Alitalo K.
    J Cell Biochem; 1991 Jan; 45(1):69-81. PubMed ID: 1706346
    [Abstract] [Full Text] [Related]

  • 3. Differential regulation of oncogenic and cellular p185 by serine/threonine kinases.
    Dobashi K, Weiner DB, Greene MI.
    DNA; 1989 Dec; 8(10):723-32. PubMed ID: 2575488
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells.
    Shawver LK, Mann E, Elliger SS, Dugger TC, Arteaga CL.
    Cancer Res; 1994 Mar 01; 54(5):1367-73. PubMed ID: 7907001
    [Abstract] [Full Text] [Related]

  • 6. Intermolecular association and trans-phosphorylation of different neu-kinase forms permit SH2-dependent signaling and oncogenic transformation.
    Qian X, Dougall WC, Fei Z, Greene MI.
    Oncogene; 1995 Jan 05; 10(1):211-9. PubMed ID: 7824275
    [Abstract] [Full Text] [Related]

  • 7. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
    Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD, Stewart SJ.
    Cancer Res; 1994 Jul 15; 54(14):3758-65. PubMed ID: 7913407
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase activity by genistein, a tyrosine kinase inhibitor.
    Tseng CP, Verma AK.
    Mol Pharmacol; 1996 Aug 15; 50(2):249-57. PubMed ID: 8700131
    [Abstract] [Full Text] [Related]

  • 10. Most of the substrates of oncogenic viral tyrosine protein kinases can be phosphorylated by cellular tyrosine protein kinases in normal cells.
    Kamps MP, Sefton BM.
    Oncogene Res; 1988 Sep 15; 3(2):105-15. PubMed ID: 2465525
    [Abstract] [Full Text] [Related]

  • 11. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene.
    Bargmann CI, Weinberg RA.
    Proc Natl Acad Sci U S A; 1988 Aug 15; 85(15):5394-8. PubMed ID: 2899890
    [Abstract] [Full Text] [Related]

  • 12. 2-Aminopurine abolishes EGF- and TPA-stimulated pp33 phosphorylation and c-fos induction without affecting the activation of protein kinase C.
    Mahadevan LC, Wills AJ, Hirst EA, Rathjen PD, Heath JK.
    Oncogene; 1990 Mar 15; 5(3):327-35. PubMed ID: 2107492
    [Abstract] [Full Text] [Related]

  • 13. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein.
    Weiner DB, Kokai Y, Wada T, Cohen JA, Williams WV, Greene MI.
    Oncogene; 1989 Oct 15; 4(10):1175-83. PubMed ID: 2571965
    [Abstract] [Full Text] [Related]

  • 14. Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins.
    Miller P, DiOrio C, Moyer M, Schnur RC, Bruskin A, Cullen W, Moyer JD.
    Cancer Res; 1994 May 15; 54(10):2724-30. PubMed ID: 7909494
    [Abstract] [Full Text] [Related]

  • 15. Tyrosine phosphorylation at the membrane-microfilament interface: a p185neu-associated signal transduction particle containing Src, Abl and phosphorylated p58, a membrane- and microfilament-associated retroviral gag-like protein.
    Juang SH, Carvajal ME, Whitney M, Liu Y, Carraway CA.
    Oncogene; 1996 Mar 07; 12(5):1033-42. PubMed ID: 8649794
    [Abstract] [Full Text] [Related]

  • 16. Interaction of the neu/p185 and EGF receptor tyrosine kinases: implications for cellular transformation and tumor therapy.
    Dougall WC, Qian X, Greene MI.
    J Cell Biochem; 1993 Sep 07; 53(1):61-73. PubMed ID: 7901229
    [Abstract] [Full Text] [Related]

  • 17. Downregulation of the early genomic growth factor response in neu oncogene-transformed cells.
    Sistonen L, Koskinen PJ, Lehväslaiho H, Lehtola L, Bravo R, Alitalo K.
    Oncogene; 1990 Jun 07; 5(6):815-21. PubMed ID: 1972791
    [Abstract] [Full Text] [Related]

  • 18. Differential heat stress stability of epidermal growth factor receptor and erbB-2 receptor tyrosine kinase activities.
    Liu SM, Carpenter G.
    J Cell Physiol; 1993 Nov 07; 157(2):237-42. PubMed ID: 7901224
    [Abstract] [Full Text] [Related]

  • 19. Regulation of the epidermal growth factor receptor by phosphorylation.
    Bertics PJ, Weber W, Cochet C, Gill GN.
    J Cell Biochem; 1985 Nov 07; 29(3):195-208. PubMed ID: 3001110
    [Abstract] [Full Text] [Related]

  • 20. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity.
    Stern DF, Heffernan PA, Weinberg RA.
    Mol Cell Biol; 1986 May 07; 6(5):1729-40. PubMed ID: 2878363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.